The UK Competition Authority disqualifies a pharmaceutical company director due to his involvement in illegal sharing of commercially sensitive information about the antidepressant nortriptyline (Pritesh Sonpal / Lexon)

KEYWORDS
Reference

UK Competition Authority, Pritesh Sonpal / Lexon, Press release, 11 January 2022

CMA disqualifies pharma director* The CMA has secured the disqualification of a pharmaceutical company director, in connection with his involvement in illegal anti-competitive practices. Pritesh Sonpal – a former director of the pharmaceutical wholesaler Lexon – will be disqualified from taking up any director role or being involved in the management of any company

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • United Kingdom’s Competition Authority - CMA (London)
    United Kingdom 279 contributions 74270 visits

Quotation

UK Competition Authority, The UK Competition Authority disqualifies a pharmaceutical company director due to his involvement in illegal sharing of commercially sensitive information about the antidepressant nortriptyline (Pritesh Sonpal / Lexon), 11 January 2022, e-Competitions January 2022, Art. N° 104682

Visites 353

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues